Meeting
2024 ASCO Annual Meeting
Debunking the frailty-sarcopenia-ADT axis in metastatic prostate cancer with multicomponent exercise: The FIERCE trial.
Authors
Christina Marie Dieli-Conwright
Dana-Farber Cancer Institute, Boston, MA
Christina Marie Dieli-Conwright , Alicia K. Morgans , Paola Gonzalo-Encabo , Dong-Woo Kang , Michael Hayden Rosenthal , Matthew Vander Heiden , Hajime Uno , Rebekah L Wilson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Hormone-Sensitive
Clinical Trial Registration Number
NCT06040125
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS5124)
DOI
10.1200/JCO.2024.42.16_suppl.TPS5124
Abstract #
TPS5124
Poster Bd #
521b
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Randomized trial of exercise vs. usual care on cancer biomarkers in ovarian cancer survivors: The Women’s Activity and Lifestyle Study in Connecticut (WALC).
First Author: Brenda Cartmel
Poster
2014 ASCO Annual Meeting
Effect of exercise on weight, body fat, and serum inflammatory biomarkers in breast cancer survivors with aromatase inhibitor arthralgias: The hormones and physical exercise (HOPE) study.
First Author: Melinda Irwin
Poster
2023 ASCO Annual Meeting
Whole-food plant-based diet (WFPBD) to control weight and metabo-inflammation in overweight/obese men with prostate cancer (PC) receiving androgen deprivation therapy (ADT): A multi-center randomized control trial.
First Author: Nicole Jacobs
Poster
2023 ASCO Annual Meeting
Biologic profile to predict overall survival in non-metastatic breast cancer: A latent class analysis on aging biomarkers.
First Author: Claire Falandry